Back to Journals » Pharmacogenomics and Personalized Medicine

Pharmacogenomics and Personalized Medicine


Journal Articles:

- 156 records -

Pharmacogenomics of sickle cell disease: steps toward personalized medicine

Husain M, Hartman AD, Desai P

Pharmacogenomics and Personalized Medicine 2017, 10:261-265

Published Date: 19 October 2017

Urine metabolic ratio of omeprazole in relation to CYP2C19 polymorphisms in Russian peptic ulcer patients

Denisenko NP, Sychev DA, Sizova ZM, Smirnov VV, Ryzhikova KA, Sozaeva ZA, Grishina EA

Pharmacogenomics and Personalized Medicine 2017, 10:253-259

Published Date: 27 September 2017

Do CYP2C19 and ABCB1 gene polymorphisms and low CYP3A4 isoenzyme activity have an impact on stent implantation complications in acute coronary syndrome patients?

Rytkin E, Mirzaev KB, Grishina EA, Smirnov VV, Ryzhikova KA, Sozaeva ZA, Giliarov MI, Andreev DA, Sychev DA

Pharmacogenomics and Personalized Medicine 2017, 10:243-245

Published Date: 18 September 2017

ABCB1 and ABCC1 single-nucleotide polymorphisms in patients treated with clozapine

Piatkov I, Caetano D, Assur Y, Lau SL, Jones T, Boyages SC, McLean M

Pharmacogenomics and Personalized Medicine 2017, 10:235-242

Published Date: 28 August 2017

Updating the landscape of direct-to-consumer pharmacogenomic testing

Filipski KK, Murphy JD, Helzlsouer KJ

Pharmacogenomics and Personalized Medicine 2017, 10:229-232

Published Date: 22 August 2017

CYP2D6 phenotypes are associated with adverse outcomes related to opioid medications

St Sauver JL, Olson JE, Roger VL, Nicholson WT, Black III JL, Takahashi PY, Caraballo PJ, Bell EJ, Jacobson DJ, Larson NB, Bielinski SJ

Pharmacogenomics and Personalized Medicine 2017, 10:217-227

Published Date: 24 July 2017

Pharmacodynamic genetic polymorphisms affect adverse drug reactions of haloperidol in patients with alcohol-use disorder

Zastrozhin MS, Brodyansky VM, Skryabin VY, Grishina EA, Ivashchenko DV, Ryzhikova KA, Savchenko LM, Kibitov AO, Bryun EA, Sychev DA

Pharmacogenomics and Personalized Medicine 2017, 10:209-215

Published Date: 7 July 2017

Hyperbilirubinemia in atazanavir treated HIV-infected patients: the impact of the UGT1A1*28 allele

Panagopoulos P, Maltezos E, Hatzakis A, Paraskevis D

Pharmacogenomics and Personalized Medicine 2017, 10:205-208

Published Date: 20 June 2017

Observational study to calculate addictive risk to opioids: a validation study of a predictive algorithm to evaluate opioid use disorder

Brenton A, Richeimer S, Sharma M, Lee C, Kantorovich S, Blanchard J, Meshkin B

Pharmacogenomics and Personalized Medicine 2017, 10:187-195

Published Date: 18 May 2017

CYP2C19*2 status in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis

Laska AJ, Han MJ, Lospinoso JA, Brown PJ, Beachkofsky TM

Pharmacogenomics and Personalized Medicine 2017, 10:183-186

Published Date: 17 May 2017

DNA methylation at the mu-1 opioid receptor gene (OPRM1) promoter predicts preoperative, acute, and chronic postsurgical pain after spine fusion

Chidambaran V, Zhang X, Martin LJ, Ding L, Weirauch MT, Geisler K, Stubbeman BL, Sadhasivam S, Ji H

Pharmacogenomics and Personalized Medicine 2017, 10:157-168

Published Date: 9 May 2017

ABCG2 polymorphisms in gout: insights into disease susceptibility and treatment approaches

Cleophas MC, Joosten LA, Stamp LK, Dalbeth N, Woodward OM, Merriman TR

Pharmacogenomics and Personalized Medicine 2017, 10:129-142

Published Date: 20 April 2017

CYP2C19 polymorphism frequency in Russian patients in Central Russia and Siberia with acute coronary syndrome

Mirzaev KB, Zelenskaya EM, Barbarash OL, Ganyukov VI, Apartsin KA, Saraeva NO, Nikolaev KY, Ryzhikova KA, Lifshits GI, Sychev DA

Pharmacogenomics and Personalized Medicine 2017, 10:107-114

Published Date: 12 April 2017

Association of the PPP3CA c.249G>A variant with clinical outcomes of tacrolimus-based therapy in kidney transplant recipients

Salgado PC, Genvigir FDV, Felipe CR, Tedesco-Silva Jr H, Medina-Pestana JO, Doi SQ, Hirata MH, Hirata RDC

Pharmacogenomics and Personalized Medicine 2017, 10:101-106

Published Date: 31 March 2017

Comparison of CYP2C9, CYP2C19, CYP2D6, ABCB1, and SLCO1B1 gene-polymorphism frequency in Russian and Nanai populations

Sychev DA, Shuev GN, Suleymanov SS, Ryzhikova KA, Mirzaev KB, Grishina EA, Snalina NE, Sozaeva ZA, Grabuzdov AM, Matsneva IA

Pharmacogenomics and Personalized Medicine 2017, 10:93-99

Published Date: 31 March 2017

MTHFR polymorphisms in childhood acute lymphoblastic leukemia: influence on methotrexate therapy

Umerez M, Gutierrez-Camino Á, Muñoz-Maldonado C, Martin-Guerrero I, Garcia-Orad A

Pharmacogenomics and Personalized Medicine 2017, 10:69-78

Published Date: 27 March 2017

UGT1A1 polymorphisms in cancer: impact on irinotecan treatment

Takano M, Sugiyama T

Pharmacogenomics and Personalized Medicine 2017, 10:61-68

Published Date: 28 February 2017

Is there evidence that we should screen the general population for Lynch syndrome with genetic testing? A systematic review

Prince AER, Cadigan RJ, Henderson GE, Evans JP, Adams M, Coker-Schwimmer E, Penn DC, Van Riper M, Corbie-Smith G, Jonas DE

Pharmacogenomics and Personalized Medicine 2017, 10:49-60

Published Date: 20 February 2017

Increased risk of hospitalization for ultrarapid metabolizers of cytochrome P450 2D6

Takahashi PY, Ryu E, Pathak J, Jenkins GD, Batzler A, Hathcock MA, Black JL, Olson JE, Cerhan JR, Bielinski SJ

Pharmacogenomics and Personalized Medicine 2017, 10:39-47

Published Date: 14 February 2017

The HLA-A*31:01 allele: influence on carbamazepine treatment

Yip VLM, Pirmohamed M

Pharmacogenomics and Personalized Medicine 2017, 10:29-38

Published Date: 31 January 2017

Prevalence of clinically actionable genotypes and medication exposure of older adults in the community

Daneshi N, Holliday E, Hancock S, Schneider JJ, Scott RJ, Attia J, Milward EA

Pharmacogenomics and Personalized Medicine 2017, 10:17-27

Published Date: 27 January 2017

Diet and lifestyle factors associated with miRNA expression in colorectal tissue

Slattery ML, Herrick JS, Mullany LE, Stevens JR, Wolff RK

Pharmacogenomics and Personalized Medicine 2017, 10:1-16

Published Date: 20 December 2016

CYP2D6 polymorphisms and their influence on risperidone treatment

Puangpetch A, Vanwong N, Nuntamool N, Hongkaew Y, Chamnanphon M, Sukasem C

Pharmacogenomics and Personalized Medicine 2016, 9:131-147

Published Date: 1 December 2016

Treatment-resistant schizophrenia: current insights on the pharmacogenomics of antipsychotics

Lally J, Gaughran F, Timms P, Curran SR

Pharmacogenomics and Personalized Medicine 2016, 9:117-129

Published Date: 7 November 2016

Pharmacogenomics of statins: understanding susceptibility to adverse effects

Kitzmiller JP, Mikulik EB, Dauki AM, Mukherjee C, Luzum JA

Pharmacogenomics and Personalized Medicine 2016, 9:97-106

Published Date: 3 October 2016

Comments on Lucire and Crotty, 2011

Loonen AJM, Verkes RJ

Pharmacogenomics and Personalized Medicine 2016, 9:85-87

Published Date: 18 August 2016

Use of combinatorial pharmacogenomic testing in two cases from community psychiatry

Fields ES, Lorenz RA, Winner JG

Pharmacogenomics and Personalized Medicine 2016, 9:79-84

Published Date: 16 August 2016

The frequency of SLCO1B1*5 polymorphism genotypes among Russian and Sakha (Yakutia) patients with hypercholesterolemia

Sychev DA, Shuev GN, Chertovskih JV, Maksimova NR, Grachev AV, Syrkova OA

Pharmacogenomics and Personalized Medicine 2016, 9:59-63

Published Date: 25 May 2016

The effect of ABCB1 polymorphisms on the outcome of breast cancer treatment

Tulsyan S, Mittal RD, Mittal B

Pharmacogenomics and Personalized Medicine 2016, 9:47-58

Published Date: 27 April 2016

Potential utility of precision medicine for older adults with polypharmacy: a case series study

Finkelstein J, Friedman C, Hripcsak G, Cabrera M

Pharmacogenomics and Personalized Medicine 2016, 9:31-45

Published Date: 15 April 2016

Initial assessment of the benefits of implementing pharmacogenetics into the medical management of patients in a long-term care facility

Saldivar JS, Taylor D, Sugarman EA, Cullors A, Garces JA, Oades K, Centeno J

Pharmacogenomics and Personalized Medicine 2016, 9:1-6

Published Date: 19 January 2016

The use of pharmacogenetics in clinical practice for the treatment of individuals with HIV infection in Thailand

Bushyakanist A, Puangpetch A, Sukasem C, Kiertiburanakul S

Pharmacogenomics and Personalized Medicine 2015, 8:163-170

Published Date: 5 November 2015

A pharmacogenomic prospective randomized controlled trial of CYP2B6 polymorphisms and efavirenz dose adjustment among HIV-infected Thai patients: a pilot study

Damronglerd P, Sukasem C, Thipmontree W, Puangpetch A, Kiertiburanakul S

Pharmacogenomics and Personalized Medicine 2015, 8:155-162

Published Date: 3 October 2015

Once-daily dose regimen of ribavirin is interchangeable with a twice-daily dose regimen: randomized open clinical trial

Balk JM, Haenen GRMM, Koc ÖM, Peters R, Bast A, van der Vijgh WJF, Koek GH

Pharmacogenomics and Personalized Medicine 2015, 8:137-144

Published Date: 12 August 2015

Olaparib in the management of ovarian cancer

Bixel K, Hays JL

Pharmacogenomics and Personalized Medicine 2015, 8:127-135

Published Date: 7 August 2015

The frequency of CYP2C19 genetic polymorphisms in Russian patients with peptic ulcers treated with proton pump inhibitors

Sychev DA, Denisenko NP, Sizova ZM, Grachev AV, Velikolug KA

Pharmacogenomics and Personalized Medicine 2015, 8:111-114

Published Date: 27 May 2015

The current and future state of companion diagnostics

Agarwal A, Ressler D, Snyder G

Pharmacogenomics and Personalized Medicine 2015, 8:99-110

Published Date: 31 March 2015

Immune cell-based screening assay for response to anticancer agents: applications in pharmacogenomics

Frick A, Fedoriw Y, Richards K, Damania B, Parks B, Suzuki O, Benton CS, Chan E, Thomas RS, Wiltshire T

Pharmacogenomics and Personalized Medicine 2015, 8:81-98

Published Date: 26 February 2015

Genomic profiling toward precision medicine in non-small cell lung cancer: getting beyond EGFR

Richer AL, Friel JM, Carson VM, Inge LJ, Whitsett TG

Pharmacogenomics and Personalized Medicine 2015, 8:63-79

Published Date: 20 February 2015

Awareness regarding clinical application of pharmacogenetics among Japanese pharmacists

Obara T, Abe S, Satoh M, Gutiérrez Ubeda SR, Yoshimachi S, Goto T

Pharmacogenomics and Personalized Medicine 2015, 8:35-41

Published Date: 29 January 2015

Targeted treatments for multiple myeloma: specific role of carfilzomib

Sugumar D, Keller J, Vij R

Pharmacogenomics and Personalized Medicine 2015, 8:23-33

Published Date: 20 January 2015

Diabetic retinopathy: variations in patient therapeutic outcomes and pharmacogenomics

Agarwal A, Soliman MK, Sepah YJ, Do DV, Nguyen QD

Pharmacogenomics and Personalized Medicine 2014, 7:399-409

Published Date: 12 December 2014

Mycophenolic acid AUC in Thai kidney transplant recipients receiving low dose mycophenolate and its association with UGT2B7 polymorphisms

Pithukpakorn M, Tiwawanwong T, Lalerd Y, Assawamakin A, Premasathian N, Tasanarong A, Thongnoppakhun W, Vongwiwatana A

Pharmacogenomics and Personalized Medicine 2014, 7:379-385

Published Date: 5 December 2014

Clinical utility of pharmacogenomics in the management of hepatitis C

Trinks J, Hulaniuk ML, Redal MA, Flichman D

Pharmacogenomics and Personalized Medicine 2014, 7:339-347

Published Date: 20 October 2014

Profiling and targeting HER2-positive breast cancer using trastuzumab emtansine

Sadeghi S, Olevsky O, Hurvitz SA

Pharmacogenomics and Personalized Medicine 2014, 7:329-338

Published Date: 15 October 2014

Pharmacogenetic information for patients on drug labels

Haga SB, Mills R, Moaddeb J

Pharmacogenomics and Personalized Medicine 2014, 7:297-305

Published Date: 3 October 2014

Tailoring therapy for heart failure: the pharmacogenomics of adrenergic receptor signaling

Femminella GD, Barrese V, Ferrara N, Rengo G

Pharmacogenomics and Personalized Medicine 2014, 7:267-273

Published Date: 9 September 2014

Developments in renal pharmacogenomics and applications in chronic kidney disease

Padullés A, Rama I, Llaudó I, Lloberas N

Pharmacogenomics and Personalized Medicine 2014, 7:251-266

Published Date: 28 August 2014

Simeprevir for the treatment of hepatitis C virus infection

Izquierdo L, Helle F, François C, Castelain S, Duverlie G, Brochot E

Pharmacogenomics and Personalized Medicine 2014, 7:241-249

Published Date: 14 August 2014

Implementation and utilization of genetic testing in personalized medicine

Abul-Husn NS, Owusu Obeng A, Sanderson SC, Gottesman O, Scott SA

Pharmacogenomics and Personalized Medicine 2014, 7:227-240

Published Date: 13 August 2014

CYP19A1 single nucleotide polymorphism associations with CYP19A1, NFκB1, and IL6 gene expression in human normal colon and normal liver samples

Penney RB, Lundgreen A, Yao-Borengasser A, Edavana VK, Williams S, Dhakal I, Wolff RK, Kadlubar S, Slattery ML

Pharmacogenomics and Personalized Medicine 2014, 7:163-171

Published Date: 14 July 2014

Personalized therapy algorithms for type 2 diabetes: a phenotype-based approach

Ceriello A, Gallo M, Candido R, De Micheli A, Esposito K, Gentile S, Medea G

Pharmacogenomics and Personalized Medicine 2014, 7:129-136

Published Date: 19 June 2014

Possible impact of the CYP2D6*10 polymorphism on the nonlinear pharmacokinetic parameter estimates of paroxetine in Japanese patients with major depressive disorders

Saruwatari J, Nakashima H, Tsuchimine S, Nishimura M, Ogusu N, Yasui-Furukori N

Pharmacogenomics and Personalized Medicine 2014, 7:121-127

Published Date: 28 April 2014

Effects of EPHX1 and CYP3A4 polymorphisms on carbamazepine metabolism in epileptic patients

Caruso A, Bellia C, Pivetti A, Agnello L, Bazza F, Scazzone C, Bivona G, Lo Sasso B, Ciaccio M

Pharmacogenomics and Personalized Medicine 2014, 7:117-120

Published Date: 2 April 2014

Targeted treatments in advanced renal cell carcinoma: focus on axitinib

Verzoni E, Grassi P, Testa I, Iacovelli R, Biondani P, Garanzini E, De Braud F, Procopio G

Pharmacogenomics and Personalized Medicine 2014, 7:107-116

Published Date: 27 March 2014

Precision medicine and personalized breast cancer: combination pertuzumab therapy

Reynolds K, Sarangi S, Bardia A, Dizon DS

Pharmacogenomics and Personalized Medicine 2014, 7:95-105

Published Date: 20 March 2014

ALK-driven tumors and targeted therapy: focus on crizotinib

Murga-Zamalloa C, Lim MS

Pharmacogenomics and Personalized Medicine 2014, 7:87-94

Published Date: 20 March 2014

Glioblastoma extracellular vesicles: reservoirs of potential biomarkers

Redzic JS, Ung TH, Graner MW

Pharmacogenomics and Personalized Medicine 2014, 7:65-77

Published Date: 13 February 2014

Molecular variants and mutations in medulloblastoma

Schroeder K, Gururangan S

Pharmacogenomics and Personalized Medicine 2014, 7:43-51

Published Date: 4 February 2014

Dabrafenib for treatment of BRAF-mutant melanoma

Kainthla R, Kim KB, Falchook GS

Pharmacogenomics and Personalized Medicine 2014, 7:21-29

Published Date: 31 December 2013

Delivering pharmacogenetic testing in a primary care setting

Mills R, Voora D, Peyser B, Haga SB

Pharmacogenomics and Personalized Medicine 2013, 6:105-112

Published Date: 18 September 2013

Lack of correlation between in silico projection of function and quantitative real-time PCR-determined gene expression levels in colon tissue

Penney RB, Lundgreen A, Yao-Borengasser A, Koroth-Edavana V, Williams S, Wolff R, Slattery ML, Kadlubar S

Pharmacogenomics and Personalized Medicine 2013, 6:99-103

Published Date: 9 September 2013

Association of CYP3A4/5, ABCB1 and ABCC2 polymorphisms and clinical outcomes of Thai breast cancer patients treated with tamoxifen

Sensorn I, Sirachainan E, Chamnanphol M, Pasomsub E, Trachu N, Supavilai P, Sukasem C, Pinthong D

Pharmacogenomics and Personalized Medicine 2013, 6:93-98

Published Date: 26 August 2013

CYP2C19 polymorphisms in the Thai population and the clinical response to clopidogrel in patients with atherothrombotic-risk factors

Sukasem C, Tunthong R, Chamnanphon M, Santon S, Jantararoungtong T, Koomdee N, Prommas S, Puangpetch A, Vathesatogkit P

Pharmacogenomics and Personalized Medicine 2013, 6:85-91

Published Date: 22 August 2013

ABCB1 haplotypes do not influence transport or efficacy of tyrosine kinase inhibitors in vitro

Skoglund K, Boiso Moreno S, Baytar M, Jönsson JI, Gréen H

Pharmacogenomics and Personalized Medicine 2013, 6:63-72

Published Date: 20 August 2013

Molecular targeted therapies in metastatic melanoma

Chakraborty R, Wieland CN, Comfere NI

Pharmacogenomics and Personalized Medicine 2013, 6:49-56

Published Date: 7 June 2013

Association of CYP2D6 and CYP2C19 polymorphisms and disease-free survival of Thai post-menopausal breast cancer patients who received adjuvant tamoxifen

Chamnanphon M, Pechatanan K, Sirachainan E, Trachu N, Chantratita W, Pasomsub E, Noonpakdee W, Sensorn I, Sukasem C

Pharmacogenomics and Personalized Medicine 2013, 6:37-48

Published Date: 24 May 2013

Non-small-cell lung cancer: molecular targeted therapy and personalized medicine – drug resistance, mechanisms, and strategies

Sechler M, Cizmic AD, Avasarala S, Van Scoyk M, Brzezinski C, Kelley N, Bikkavilli RK, Winn RA

Pharmacogenomics and Personalized Medicine 2013, 6:25-36

Published Date: 4 April 2013

Copy number variation in sulfotransferase isoform 1A1 (SULT1A1) is significantly associated with enzymatic activity in Japanese subjects

Yu X, Kubota T, Dhakal I, Hasegawa S, Williams S, Ozawa S, Kadlubar S

Pharmacogenomics and Personalized Medicine 2013, 6:19-24

Published Date: 6 March 2013

GSTM1 copy number and promoter haplotype as predictors for risk of recurrence and/or second primary tumor in patients with head and neck cancer

Zhang X, Huang M, Wu X, Kadlubar S, Lin J, Yu X, Fan C, Ning B, Kadlubar FF

Pharmacogenomics and Personalized Medicine 2013, 6:9-17

Published Date: 1 March 2013

Importance of pharmacogenetics in the treatment of children with attention deficit hyperactive disorder: a case report

Tan-kam T, Suthisisang C, Pavasuthipaisit C, Limsila P, Puangpetch A, Sukasem C

Pharmacogenomics and Personalized Medicine 2013, 6:3-7

Published Date: 11 January 2013

Pharmacogenomic considerations in opioid analgesia. [Corrigendum]

Vuilleumier PH, Stamer UM, Landau R

Pharmacogenomics and Personalized Medicine 2013, 6:1-2

Published Date: 14 January 2013

CYP2D6 polymorphisms influence the efficacy of adjuvant tamoxifen in Thai breast cancer patients

Sirachainan E, Jaruhathai S, Trachu N, Panvichian R, Sirisinha T, Ativitavas T, Ratanatharathorn V, Chamnanphon M, Sukasem C

Pharmacogenomics and Personalized Medicine 2012, 5:149-153

Published Date: 17 October 2012

Drug targets and predictive biomarkers in the management of metastatic melanoma

Thumar J, Giesen E, Kluger HM

Pharmacogenomics and Personalized Medicine 2012, 5:139-148

Published Date: 28 September 2012

Boceprevir and personalized medicine in hepatitis C virus infection

Habersetzer F, Leboeuf C, Doffoël M, Baumert TF

Pharmacogenomics and Personalized Medicine 2012, 5:125-137

Published Date: 26 September 2012

Mu opioid receptor (OPRM1) as a predictor of treatment outcome in opiate-dependent individuals of Arab descent

AL-Eitan LN, Jaradat SA, Su SY, Tay GK, Hulse GK

Pharmacogenomics and Personalized Medicine 2012, 5:99-111

Published Date: 7 September 2012

Role of pharmacogenomics in the treatment of tuberculosis: a review

Ramachandran G, Swaminathan S

Pharmacogenomics and Personalized Medicine 2012, 5:89-98

Published Date: 13 September 2012

Pharmacogenomic considerations in opioid analgesia

Vuilleumier PH, Stamer UM, Landau R

Pharmacogenomics and Personalized Medicine 2012, 5:73-87

Published Date: 23 August 2012

ABCB1 haplotype and OPRM1 118A > G genotype interaction in methadone maintenance treatment pharmacogenetics

Barratt DT, Coller JK, Hallinan R, Byrne A, White JM, Foster DJR, Somogyi AA

Pharmacogenomics and Personalized Medicine 2012, 5:53-62

Published Date: 18 April 2012

Association of the 5-HTT gene-linked promoter region (5-HTTLPR) polymorphism with psychiatric disorders: review of psychopathology and pharmacotherapy

Kenna GA, Roder-Hanna N, Leggio L, Zywiak WH, Clifford J, Edwards S, Kenna JA, Shoaff J, Swift RM

Pharmacogenomics and Personalized Medicine 2012, 5:19-35

Published Date: 13 January 2012

Individualization of antiretroviral therapy

Pavlos R, Phillips EJ

Pharmacogenomics and Personalized Medicine 2012, 5:1-17

Published Date: 29 December 2011

Sulfation of fulvestrant by human liver cytosols and recombinant SULT1A1 and SULT1E1

Edavana VK, Yu X, Dhakal IB, Williams S, Ning B, Cook IT, Caldwell D, Falany CN, Kadlubar S

Pharmacogenomics and Personalized Medicine 2011, 4:137-145

Published Date: 17 November 2011

Role of cytochrome P450 genotype in the steps toward personalized drug therapy

Cavallari LH, Jeong H, Bress A

Pharmacogenomics and Personalized Medicine 2011, 4:123-136

Published Date: 7 November 2011

Clinical implementation of RNA signatures for pharmacogenomic decision-making

Tang W, Hu Z, Muallem H, Gulley ML

Pharmacogenomics and Personalized Medicine 2011, 4:95-107

Published Date: 8 September 2011

Role of 5-HT2C receptor gene variants in antipsychotic-induced weight gain

Wallace TJM, Zai CC, Brandl EJ, Müller DJ

Pharmacogenomics and Personalized Medicine 2011, 4:83-93

Published Date: 18 August 2011

ERCC1 and XRCC1 as biomarkers for lung and head and neck cancer

Vaezi A, Feldman CH, Niedernhofer LJ

Pharmacogenomics and Personalized Medicine 2011, 4:47-63

Published Date: 20 July 2011

A genetic approach to the prediction of drug side effects: bleomycin induces concordant phenotypes in mice of the collaborative cross

Gelinas R, Chesler EJ, Vasconcelos D, Miller DR, Yuan Y, Wang K, Galas D

Pharmacogenomics and Personalized Medicine 2011, 4:35-45

Published Date: 4 July 2011

Optimizing response to gefitinib in the treatment of non-small-cell lung cancer

Pietro Carotenuto, Cristin Roma, Anna Maria Rachiglio, et al

Pharmacogenomics and Personalized Medicine 2011, 4:1-9

Published Date: 14 March 2011

Pharmacogenetics in breast cancer: steps toward personalized medicine in breast cancer management

Sarah Rofaiel, Esther N Muo, Shaker A Mousa

Pharmacogenomics and Personalized Medicine 2010, 3:129-143

Published Date: 17 September 2010

The future role of personalized medicine in the treatment of glioblastoma multiforme

Jing Li, Chunhui Di, Austin K Mattox, et al

Pharmacogenomics and Personalized Medicine 2010, 3:111-127

Published Date: 19 August 2010

Antiplatelet agents and proton pump inhibitors – personalizing treatment

Eugene Lin, Rajiv Padmanabhan, Majaz Moonis

Pharmacogenomics and Personalized Medicine 2010, 3:101-109

Published Date: 28 June 2010

Impact of genetic polymorphisms on clinical response to antithrombotics

Kena J Lanham, Julie H Oestreich, Steven P Dunn, et al

Pharmacogenomics and Personalized Medicine 2010, 3:87-99

Published Date: 18 June 2010

Update and developments in the treatment of glioblastoma multiforme – focus on bevacizumab

Naveed Wagle, Leia Nghiemphu, Albert Lai, et al

Pharmacogenomics and Personalized Medicine 2010, 3:79-85

Published Date: 9 June 2010

DRD4 and DAT1 in ADHD: Functional neurobiology to pharmacogenetics

Darko Turic, James Swanson, Edmund Sonuga-Barke

Pharmacogenomics and Personalized Medicine 2010, 3:61-78

Published Date: 21 May 2010

Determinants to optimize response to clopidogrel in acute coronary syndrome

Betti Giusti, Anna Maria Gori, Rossella Marcucci, et al

Pharmacogenomics and Personalized Medicine 2010, 3:33-50

Published Date: 8 April 2010

Pharmacogenomics in type II diabetes mellitus management: Steps toward personalized medicine

Peter Avery, Shaymaa S Mousa, Shaker A Mousa

Pharmacogenomics and Personalized Medicine 2009, 2:79-91

Published Date: 13 September 2009

Pharmacogenomics in osteoporosis: Steps toward personalized medicine

Robert Greene, Shaymaa S Mousa, Mohamed Ardawi, et al

Pharmacogenomics and Personalized Medicine 2009, 2:69-78

Published Date: 10 September 2009

Genomics and proteomics: Applications in autoimmune diseases

Wolfgang Hueber, William H Robinson

Pharmacogenomics and Personalized Medicine 2009, 2:39-48

Published Date: 17 August 2009

Lack of association between the A118G polymorphism of the mu opioid receptor gene (OPRM1) and opioid  dependence: A meta-analysis

Janet K Coller, Julia Beardsley, James Bignold, Yibai Li, Florence Merg, et al

Pharmacogenomics and Personalized Medicine 2009, 2:9-19

Published Date: 20 March 2009

Pharmacogenomic application of the haptoglobin genotype in the treatment of HDL dysfunction

Avery Schwartz, Shany Blum, Rabea Asleh, Mordechai Pollak, Shiri Kalet-Litman, Andrew P Levy

Pharmacogenomics and Personalized Medicine 2009, 2:1-8

Published Date: 27 February 2009

Integrating epigenomics into pharmacogenomic studies

Wei Zhang, R Stephanie Huang, M Eileen Dolan

Pharmacogenomics and Personalized Medicine 2008, 1:7-14

Published Date: 2 November 2008